Evaluation of multimodality treatment of locoregional esophageal carcinoma by southwest oncology Group 9060

Elizabeth A. Poplin, Joth Jacobson, Arnold Herskovic, Timothy Panella, Manuel Valdivieso, Laura F. Hutchins, John S. Macdonald

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND. Continuous infusion 5-fluorouracil (C15-FU) has been utilized concurrently with radiotherapy to improve tumor control. In this pilot trial, cisplatin, C15FU, and radiotherapy were utilized for the treatment of locoregional esophageal carcinoma. It was postulated that the combination would be well tolerated and associated with high response rate and survival duration. METHODS. Thirty-two eligible patients with locoregional squamous cell carcinoma nd adenocarcinoma of the esophagus received a regimen consisting of the following: radiotherapy, 50 Gray (Gy) (30 Gy anteroposterior/posteroanterior regional with 20 Gy AP/LPO/RPO boost) over 5 weeks, with C15-FU 250 mg/m2/d for the duration of radiotherapy cisplatin 25 mg/m2/day on Days 1-3 during Weeks 1 and 4 of the radiotherapy cycle. Upon completion of radiotherapy, two additional courses of cisplatin 75 mg/m2 on Days 1 and 29 and C15-FU 300 mg/m2/day on Days 1-21 and 29-50 were delivered. Following imaging and endoscopic reassessment, patients with no evidence of disease received more chemotherapy. Surgery was suggested only for patient with residual local disease. RESULTS. Complete response was demonstrated in 44% of patients, clinically in 12 patients, and during surgery in 2 others. The median survival was 20 months, and the 1-year survival rate was 59%. Toxicity was severe, comprised of esophagitis, infection, and gastrointestinal complications. Does delays and reductions occurred in the majority of patients. Four early deaths were noted. CONCLUSIONS. The regimen that was focus of this trial has been active in the treatment of esophageal carcinoma. However, compared with existing regimens, its complexity and toxicity preclude its future use without modifications.

Original languageEnglish (US)
Pages (from-to)1851-1856
Number of pages6
JournalCancer
Volume78
Issue number9
DOIs
StatePublished - Nov 1 1996

Fingerprint

Radiotherapy
Carcinoma
Cisplatin
Therapeutics
Survival Rate
Esophagitis
Fluorouracil
Squamous Cell Carcinoma
Drug Therapy
Survival
Infection
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Evaluation of multimodality treatment of locoregional esophageal carcinoma by southwest oncology Group 9060. / Poplin, Elizabeth A.; Jacobson, Joth; Herskovic, Arnold; Panella, Timothy; Valdivieso, Manuel; Hutchins, Laura F.; Macdonald, John S.

In: Cancer, Vol. 78, No. 9, 01.11.1996, p. 1851-1856.

Research output: Contribution to journalArticle

Poplin, Elizabeth A. ; Jacobson, Joth ; Herskovic, Arnold ; Panella, Timothy ; Valdivieso, Manuel ; Hutchins, Laura F. ; Macdonald, John S. / Evaluation of multimodality treatment of locoregional esophageal carcinoma by southwest oncology Group 9060. In: Cancer. 1996 ; Vol. 78, No. 9. pp. 1851-1856.
@article{84f243802f1f437d986e0eaecfa3946d,
title = "Evaluation of multimodality treatment of locoregional esophageal carcinoma by southwest oncology Group 9060",
abstract = "BACKGROUND. Continuous infusion 5-fluorouracil (C15-FU) has been utilized concurrently with radiotherapy to improve tumor control. In this pilot trial, cisplatin, C15FU, and radiotherapy were utilized for the treatment of locoregional esophageal carcinoma. It was postulated that the combination would be well tolerated and associated with high response rate and survival duration. METHODS. Thirty-two eligible patients with locoregional squamous cell carcinoma nd adenocarcinoma of the esophagus received a regimen consisting of the following: radiotherapy, 50 Gray (Gy) (30 Gy anteroposterior/posteroanterior regional with 20 Gy AP/LPO/RPO boost) over 5 weeks, with C15-FU 250 mg/m2/d for the duration of radiotherapy cisplatin 25 mg/m2/day on Days 1-3 during Weeks 1 and 4 of the radiotherapy cycle. Upon completion of radiotherapy, two additional courses of cisplatin 75 mg/m2 on Days 1 and 29 and C15-FU 300 mg/m2/day on Days 1-21 and 29-50 were delivered. Following imaging and endoscopic reassessment, patients with no evidence of disease received more chemotherapy. Surgery was suggested only for patient with residual local disease. RESULTS. Complete response was demonstrated in 44{\%} of patients, clinically in 12 patients, and during surgery in 2 others. The median survival was 20 months, and the 1-year survival rate was 59{\%}. Toxicity was severe, comprised of esophagitis, infection, and gastrointestinal complications. Does delays and reductions occurred in the majority of patients. Four early deaths were noted. CONCLUSIONS. The regimen that was focus of this trial has been active in the treatment of esophageal carcinoma. However, compared with existing regimens, its complexity and toxicity preclude its future use without modifications.",
author = "Poplin, {Elizabeth A.} and Joth Jacobson and Arnold Herskovic and Timothy Panella and Manuel Valdivieso and Hutchins, {Laura F.} and Macdonald, {John S.}",
year = "1996",
month = "11",
day = "1",
doi = "10.1002/(SICI)1097-0142(19961101)78:9<1851::AID-CNCR2>3.0.CO;2-I",
language = "English (US)",
volume = "78",
pages = "1851--1856",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Evaluation of multimodality treatment of locoregional esophageal carcinoma by southwest oncology Group 9060

AU - Poplin, Elizabeth A.

AU - Jacobson, Joth

AU - Herskovic, Arnold

AU - Panella, Timothy

AU - Valdivieso, Manuel

AU - Hutchins, Laura F.

AU - Macdonald, John S.

PY - 1996/11/1

Y1 - 1996/11/1

N2 - BACKGROUND. Continuous infusion 5-fluorouracil (C15-FU) has been utilized concurrently with radiotherapy to improve tumor control. In this pilot trial, cisplatin, C15FU, and radiotherapy were utilized for the treatment of locoregional esophageal carcinoma. It was postulated that the combination would be well tolerated and associated with high response rate and survival duration. METHODS. Thirty-two eligible patients with locoregional squamous cell carcinoma nd adenocarcinoma of the esophagus received a regimen consisting of the following: radiotherapy, 50 Gray (Gy) (30 Gy anteroposterior/posteroanterior regional with 20 Gy AP/LPO/RPO boost) over 5 weeks, with C15-FU 250 mg/m2/d for the duration of radiotherapy cisplatin 25 mg/m2/day on Days 1-3 during Weeks 1 and 4 of the radiotherapy cycle. Upon completion of radiotherapy, two additional courses of cisplatin 75 mg/m2 on Days 1 and 29 and C15-FU 300 mg/m2/day on Days 1-21 and 29-50 were delivered. Following imaging and endoscopic reassessment, patients with no evidence of disease received more chemotherapy. Surgery was suggested only for patient with residual local disease. RESULTS. Complete response was demonstrated in 44% of patients, clinically in 12 patients, and during surgery in 2 others. The median survival was 20 months, and the 1-year survival rate was 59%. Toxicity was severe, comprised of esophagitis, infection, and gastrointestinal complications. Does delays and reductions occurred in the majority of patients. Four early deaths were noted. CONCLUSIONS. The regimen that was focus of this trial has been active in the treatment of esophageal carcinoma. However, compared with existing regimens, its complexity and toxicity preclude its future use without modifications.

AB - BACKGROUND. Continuous infusion 5-fluorouracil (C15-FU) has been utilized concurrently with radiotherapy to improve tumor control. In this pilot trial, cisplatin, C15FU, and radiotherapy were utilized for the treatment of locoregional esophageal carcinoma. It was postulated that the combination would be well tolerated and associated with high response rate and survival duration. METHODS. Thirty-two eligible patients with locoregional squamous cell carcinoma nd adenocarcinoma of the esophagus received a regimen consisting of the following: radiotherapy, 50 Gray (Gy) (30 Gy anteroposterior/posteroanterior regional with 20 Gy AP/LPO/RPO boost) over 5 weeks, with C15-FU 250 mg/m2/d for the duration of radiotherapy cisplatin 25 mg/m2/day on Days 1-3 during Weeks 1 and 4 of the radiotherapy cycle. Upon completion of radiotherapy, two additional courses of cisplatin 75 mg/m2 on Days 1 and 29 and C15-FU 300 mg/m2/day on Days 1-21 and 29-50 were delivered. Following imaging and endoscopic reassessment, patients with no evidence of disease received more chemotherapy. Surgery was suggested only for patient with residual local disease. RESULTS. Complete response was demonstrated in 44% of patients, clinically in 12 patients, and during surgery in 2 others. The median survival was 20 months, and the 1-year survival rate was 59%. Toxicity was severe, comprised of esophagitis, infection, and gastrointestinal complications. Does delays and reductions occurred in the majority of patients. Four early deaths were noted. CONCLUSIONS. The regimen that was focus of this trial has been active in the treatment of esophageal carcinoma. However, compared with existing regimens, its complexity and toxicity preclude its future use without modifications.

UR - http://www.scopus.com/inward/record.url?scp=0029851204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029851204&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19961101)78:9<1851::AID-CNCR2>3.0.CO;2-I

DO - 10.1002/(SICI)1097-0142(19961101)78:9<1851::AID-CNCR2>3.0.CO;2-I

M3 - Article

C2 - 8909302

AN - SCOPUS:0029851204

VL - 78

SP - 1851

EP - 1856

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -